A Phase 3 interventional study of Aripiprazole depot and Placebo depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 110 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-07-19.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 5th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 50th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 843 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2008, is one of 50 in phase 3, and was the 25th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.
This was a randomized, double-blind, placebo-controlled study consisting of a screening phase and 4 treatment phases. Eligibility was determined during a screening phase of 2 to 42 days. Patients receiving oral treatment with an antipsychotic other than non-generic aripiprazole entered Phase 1. Patients with a lapse in aripiprazole or other antipsychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) entered directly into Phase 2. During Phase 1 (oral conversion), patients were cross-titrated during weekly visits from other antipsychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (a minimum of 4 weeks and a maximum of 12 weeks in duration), patients were assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria were met in Phase 2, patients entered the single-blind aripiprazole intramuscular (IM) depot stabilization phase, Phase 3. In Phase 3, patients were stabilized on aripiprazole IM depot for 12 consecutive weeks. Once the patient met the stability criteria, they were eligible to be randomized into the double-blind phase, Phase 4. Patients were randomized in a 2:1 ratio (aripiprazole IM depot vs placebo IM depot) stratified by region and last aripiprazole IM depot injection dose level in Phase 3. During Phase 4, patients were assessed for impending relapse/exacerbation of psychotic symptoms. If a patient was identified with impending relapse/exacerbation of psychotic symptoms, they were withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248. Patients that completed Phase 4 (up to and including Week 52) had the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
Drug: Aripiprazole depot
Patients received placebo intramuscularly every 28 days for 52 weeks.
Drug: Placebo depot
Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Also known as: Abilify
Placebo depot was supplied in 400 mg lyophilized vials.
Time to Exacerbation of Psychotic Symptoms/Impending Relapse
A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
This is the key secondary Outcome Measure.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Percentage of Responders
A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Percentage of Patients Achieving Remission
A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Mean Change From Baseline in the PANSS Total Score
The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Mean Change From Baseline in the PANSS Positive Subscale Score
The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Mean Change From Baseline in the PANSS Negative Subscale Score
The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Mean Clinical Global Impression-Improvement (CGI-I) Score
The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
Time to Discontinuation
Time to discontinuation was defined as the date of randomization to the date of study discontinuation.
Time frame: Baseline of the depot maintenance phase to the end of the study (Week 52)
| Milestone | All Patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|---|
| Started | 633 | 0 | 0 |
| Received study medication | 632 | 0 | 0 |
| Completed | 500 | 0 | 0 |
| Not completed | 133 | 0 | 0 |
| Withdrew: Sponsor discontinued study | 54 | 0 | 0 |
| Withdrew: Lost to follow-up | 13 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 4 | 0 | 0 |
| Withdrew: Withdrawn by investigator | 4 | 0 | 0 |
| Withdrew: Withdrew consent | 24 | 0 | 0 |
| Withdrew: Protocol deviation | 2 | 0 | 0 |
| Withdrew: Adverse event | 11 | 0 | 0 |
| Withdrew: Lack of efficacy with adverse event | 13 | 0 | 0 |
| Withdrew: Lack of efficacy without adverse event | 8 | 0 | 0 |
| Milestone | All Patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|---|
| Started | 710 | 0 | 0 |
| Received study medication | 709 | 0 | 0 |
| Completed | 576 | 0 | 0 |
| Not completed | 134 | 0 | 0 |
| Withdrew: Sponsor discontinue study | 42 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 19 | 0 | 0 |
| Withdrew: Withdrawn by investigator | 12 | 0 | 0 |
| Withdrew: Withdrew consent | 29 | 0 | 0 |
| Withdrew: Adverse event | 14 | 0 | 0 |
| Withdrew: Lack of efficacy with adverse event | 7 | 0 | 0 |
| Withdrew: Lack of efficacy without adverse event | 4 | 0 | 0 |
| Milestone | All Patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|---|
| Started | 576 | 0 | 0 |
| Completed | 403 | 0 | 0 |
| Not completed | 173 | 0 | 0 |
| Withdrew: Sponsor discontinued study | 86 | 0 | 0 |
| Withdrew: Lost to follow-up | 11 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 8 | 0 | 0 |
| Withdrew: Withdrawn by investigator | 9 | 0 | 0 |
| Withdrew: Withdrew consent | 29 | 0 | 0 |
| Withdrew: Adverse event | 17 | 0 | 0 |
| Withdrew: Lack of efficacy with adverse event | 12 | 0 | 0 |
| Withdrew: Lack of efficacy without adverse event | 1 | 0 | 0 |
| Milestone | All Patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|---|
| Started | 0 | 269 | 134 |
| Completed | 0 | 23 | 3 |
| Not completed | 0 | 246 | 131 |
| Withdrew: Sponsor discontinued study | 0 | 179 | 58 |
| Withdrew: Lost to follow-up | 0 | 5 | 3 |
| Withdrew: Met withdrawal criteria | 0 | 2 | 2 |
| Withdrew: Withdrawn by investigator | 0 | 8 | 6 |
| Withdrew: Withdrew consent | 0 | 14 | 4 |
| Withdrew: Protocol deviation | 0 | 2 | 0 |
| Withdrew: Adverse event without impending relapse | 0 | 9 | 5 |
| Withdrew: Impending relapse with adverse event | 0 | 11 | 13 |
| Withdrew: Impending relapse without adverse event | 0 | 16 | 40 |
A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.
| Days | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Time to Exacerbation of Psychotic Symptoms/Impending Relapse | NA (NA to NA) | 209 (161 to 254) |
This is the key secondary Outcome Measure.
| Percentage of patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria | 10.0 | 39.6 |
A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.
| Percentage of patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Percentage of Responders | 87.6 | 56.0 |
A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).
| Percentage of patients | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Percentage of Patients Achieving Remission | 52.9 | 38.7 |
The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
| Units on a scale | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Mean Change From Baseline in the PANSS Total Score | 1.43 ± 0.756 | 11.55 ± 1.066 |
The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.
| Units on a scale | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score | 0.14 ± 0.051 | 0.66 ± 0.073 |
The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
| Units on a scale | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Mean Change From Baseline in the PANSS Positive Subscale Score | 0.44 ± 0.265 | 4.25 ± 0.374 |
The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.
| Units on a scale | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Mean Change From Baseline in the PANSS Negative Subscale Score | 0.19 ± 0.201 | 1.55 ± 0.284 |
The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.
| Units on a scale | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Mean Clinical Global Impression-Improvement (CGI-I) Score | 3.70 ± 1.05 | 4.53 ± 1.23 |
Time to discontinuation was defined as the date of randomization to the date of study discontinuation.
| Days | Aripiprazole Depot | Placebo Depot |
|---|---|---|
| Time to Discontinuation | NA (364 to NA) | 162 (98 to 211) |
Collected over Adverse events were reported from the time of the signing of informed consent until the end of the study (up to 106 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Conversion Phase | — | 13/632 (2.1%) | 113/632 (17.9%) |
| Oral Stabilization Phase | — | 10/709 (1.4%) | 50/709 (7.1%) |
| Depot Stabilization Phase | — | 25/576 (4.3%) | 184/576 (31.9%) |
| Aripiprazole Depot - Depot Maintenance Phase | — | 11/269 (4.1%) | 103/269 (38.3%) |
| Placebo Depot - Depot Maintenance Phase | — | 9/134 (6.7%) | 43/134 (32.1%) |
| Event | Conversion Phase | Oral Stabilization Phase | Depot Stabilization Phase | Aripiprazole Depot - Depot Maintenance Phase | Placebo Depot - Depot Maintenance Phase |
|---|---|---|---|---|---|
| Psychotic disorderPsychiatric disorders | 2/632 | 1/709 | 2/576 | 4/269 | 4/134 |
| SchizophreniaPsychiatric disorders | 6/632 | 6/709 | 9/576 | 2/269 | 2/134 |
| Sinus bradycardiaCardiac disorders | 0/632 | 0/709 | 0/576 | 0/269 | 1/134 |
| DiarrhoeaGastrointestinal disorders | 0/632 | 0/709 | 0/576 | 0/269 | 1/134 |
| Biliary colicHepatobiliary disorders | 0/632 | 0/709 | 0/576 | 0/269 | 1/134 |
| Grand mal convulsionNervous system disorders | 0/632 | 0/709 | 0/576 | 0/269 | 1/134 |
| Suicidal ideationPsychiatric disorders | 2/632 | 0/709 | 0/576 | 2/269 | 0/134 |
| Gun shot woundInjury, poisoning and procedural complications | 0/632 | 0/709 | 0/576 | 1/269 | 0/134 |
| InjuryInjury, poisoning and procedural complications | 0/632 | 0/709 | 0/576 | 1/269 | 0/134 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/632 | 0/709 | 0/576 | 1/269 | 0/134 |
| Event | Conversion Phase | Oral Stabilization Phase | Depot Stabilization Phase | Aripiprazole Depot - Depot Maintenance Phase | Placebo Depot - Depot Maintenance Phase |
|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 76/632 | 50/709 | 46/576 | 27/269 | 12/134 |
| Weight increasedInvestigations | 8/632 | 16/709 | 40/576 | 26/269 | 13/134 |
| AnxietyPsychiatric disorders | 27/632 | 29/709 | 38/576 | 16/269 | 10/134 |
| HeadacheNervous system disorders | 45/632 | 23/709 | 34/576 | 16/269 | 7/134 |
| AkathisiaNervous system disorders | 30/632 | 33/709 | 36/576 | 15/269 | 8/134 |
| TremorNervous system disorders | 16/632 | 14/709 | 21/576 | 16/269 | 2/134 |
| Injection site painGeneral disorders | 0/632 | 2/709 | 34/576 | 8/269 | 5/134 |
| NasopharyngitisInfections and infestations | 14/632 | 6/709 | 11/576 | 10/269 | 7/134 |
Baseline measures are based on the participants from the Depot Maintenance Phase.
| Age Continuous(years) | Aripiprazole Depot | Placebo Depot | Total |
|---|---|---|---|
| Mean | 40.1 ± 11.0 | 41.7 ± 10.5 | 40.6 ± 10.8 |
| Sex: Female, Male(Participants) | Aripiprazole Depot | Placebo Depot | Total |
|---|---|---|---|
| Female | 107 | 55 | 162 |
| Male | 162 | 79 | 241 |
Showing the first 100 of 110 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2008, a primary completion of Aug 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years 11 months after primary completion. A results delay was requested in Sep 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →